Erowid References Database
“The scheduling of MDMA: a pharmacist's perspective”.
J Psychoactive Drugs. 1985;17(3):167-71.
The United States Drug Enforcement Administration (DEA) attempted last year to place the drug 3,4- methylenedioxymethamphetamine (MDMA) in Schedule I of the Controlled Substances Act without holding public hearings on the matter. In order to place a drug in Schedule I, it must be shown to have both high abuse potential and no accepted medical use in the United States. This author was one of a number of health care professionals who filed formal protests that compelled the DEA to set up three such hearings through the latter part of 1985--one in Los Angeles, one in Kansas City and another in Washington, D.C. The following is adapted from the author's original letter of protest to the DEA and her written testimony as a scheduled witness endorsing MDMA's low potential for abuse and beneficial therapeutic applications.
[ Cite HTML